Elevated Platelet Count as Prognostic Factor in Colorectal Cancer With Synchronous Liver Metastases

Completed

• Conditions: Colorectal Carcinoma; Colorectal Cancer; Stage IV Colon Cancer
• Interventions: Diagnostic Test: Measurement of platelet count at diagnosis

• Registration Number: NCT03717519
• Lead Sponsor: Azienda Ospedaliera Universitaria Integrata Verona

Brief Summary

Colorectal cancer (CRC) is the third most common malignancy worldwide and is often metastatic at diagnosis. Despite progresses in surgical techniques and the introduction of novel chemotherapy regimens, many patients still suffer from a poor prognosis. It is therefore of utmost importance to identify prognostic markers that may improve selection of patients.

In recent years several studies demonstrated that preoperative blood tests as platelet count or neuthophil-to-lymphocyte ratio could be prognostic factors in CRC as well as other malignancies. The aim of this study was to evaluate the role of preoperative platelet count (PC) in patients with synchronous colorectal liver metastases.

Detailed Description

Not available

Study Timeline

• Study Start: 2018-01-01
• Primary Completion: 2018-05-01
• Study Completion: 2018-09-01
• Study First Submitted: 2018-10-22
• Study First Submitted QC: 2018-10-23
• Study First Posted: 2018-10-24
• Status Verified: 2023-07
• Last Update Submitted: 2023-07-19
• Last Update Posted: 2023-07-20

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 196

Inclusion Criteria

• Colorectal cancer with synchronous liver metastases
• Possibility to retrieve pre-operative platelet count
• Age of 18 years or older
• Availabilty of clinical-pathological data
• Minimum follow up of 12 months

Exclusion Criteria

• None

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
s-CRLM	Measurement of platelet count at diagnosis	Patients with synchronous colorectal liver metastases who underwent surgical resection

Primary Outcome Measures

Name	Time	Method
Overall survival	5 years	correlation between high PC and overall survival

Secondary Outcome Measures

Name	Time	Method
Clinic-pathological variables	30 days	correlation between high PC and clinic-pathological variables

Trial Locations

Locations (1)

Chirurgia Generale ed Epatobiliare, Policlinico GB Rossi; 🇮🇹 Verona, Italy